The effectiveness of pneumococcal polysaccharide vaccination in HIV-infected adults: A systematic review

HIV Medicine

Volumn 12, Issue 6, 2011, Pages 323-333

  Pedersen, R H ^a   Lohse, N ^b   Ostergaard L ^a   Sogaard O S ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b UNAIDS   (Switzerland)

Author keywords

HIV; Pneumococcal disease; Pneumococcal vaccines; Pneumonia; Streptococcus pneumoniae

Indexed keywords

PLACEBO; PNEUMOCOCCUS VACCINE;

BIOMEDICINE; CD4 LYMPHOCYTE COUNT; COCHRANE LIBRARY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG USE; EMBASE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; MEDLINE; PEER REVIEW; PNEUMOCOCCAL INFECTION; PNEUMONIA; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ADULT; EVIDENCE-BASED MEDICINE; FEMALE; HIV INFECTIONS; HUMANS; MALE; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; UGANDA;

EID: 79952473103     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2010.00892.x     Document Type: Review

References (50)

1. Feikin DR, Feldman C, Schuchat A, Janoff EN. Global strategies to prevent bacterial pneumonia in adults with HIV disease. Lancet Infect Dis 2004; 4: 445-455.
2. Kohli R, Lo Y, Homel P et al. Bacterial pneumonia, HIV therapy, and disease progression among HIV-infected women in the HIV epidemiologic research (HER) study. Clin Infect Dis 2006; 43: 90-98.
3. Sogaard OS, Lohse N, Gerstoft J et al. Hospitalization for pneumonia among individuals with and without HIV infection, 1995-2007: a Danish population-based, nationwide cohort study. Clin Infect Dis 2008; 47: 1345-1353.
4. Barry PM, Zetola N, Keruly JC, Moore RD, Gebo KA, Lucas GM. Invasive pneumococcal disease in a cohort of HIV-infected adults: incidence and risk factors, 1990-2003. AIDS 2006; 20: 437-444.
5. Foster D, Knox K, Walker AS et al. Invasive pneumococcal disease: epidemiology in children and adults prior to implementation of the conjugate vaccine in the Oxfordshire region, England. J Med Microbiol 2008; 57: 480-487.
6. Grau I, Pallares R, Tubau F et al. Epidemiologic changes in bacteremic pneumococcal disease in patients with human immunodeficiency virus in the era of highly active antiretroviral therapy. Arch Intern Med 2005; 165: 1533-1540.
7. Simberkoff MS, El Sadr W, Schiffman G, Rahal JJ Jr. Streptococcus pneumoniae infections and bacteremia in patients with acquired immune deficiency syndrome, with report of a pneumococcal vaccine failure. Am Rev Respir Dis 1984; 130: 1174-1176.
8. Ammann AJ, Schiffman G, Abrams D, Volberding P, Ziegler J, Conant M. B-cell immunodeficiency in acquired immune deficiency syndrome. JAMA 1984; 251: 1447-1449.
9. Nielsen H, Kvinesdal B, Benfield TL, Lundgren JD, Konradsen HB. Rapid loss of specific antibodies after pneumococcal vaccination in patients with human immunodeficiency virus-1 infection. Scand J Infect Dis 1998; 30: 597-601.
10. Rodriguez-Barradas MC, Groover JE, Lacke CE et al. IgG antibody to pneumococcal capsular polysaccharide in human immunodeficiency virus-infected subjects: persistence of antibody in responders, revaccination in nonresponders, and relationship of immunoglobulin allotype to response. J Infect Dis 1996; 173: 1347-1353.
11. Madhi SA, Adrian P, Cotton MF et al. Effect of HIV infection status and anti-retroviral treatment on quantitative and qualitative antibody responses to pneumococcal conjugate vaccine in infants. J Infect Dis 2010; 202: 355-361.
12. Rodriguez-Barradas MC, Alexandraki I, Nazir T et al. Response of human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy to vaccination with 23-valent pneumococcal polysaccharide vaccine. Clin Infect Dis 2003; 37: 438-447.
13. Subramaniam KS, Segal R, Lyles RH, Rodriguez-Barradas MC, Pirofski LA. Qualitative change in antibody responses of human immunodeficiency virus-infected individuals to pneumococcal capsular polysaccharide vaccination associated with highly active antiretroviral therapy. J Infect Dis 2003; 187: 758-768.
14. French N, Nakiyingi J, Carpenter LM et al. 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial. Lancet 2000; 355: 2106-2111.
15. Breiman RF, Keller DW, Phelan MA et al. Evaluation of effectiveness of the 23-valent pneumococcal capsular polysaccharide vaccine for HIV-infected patients. Arch Intern Med 2000; 160: 2633-2638.
16. Dworkin MS, Ward JW, Hanson DL, Jones JL, Kaplan JE. Pneumococcal disease among human immunodeficiency virus-infected persons: incidence, risk factors, and impact of vaccination. Clin Infect Dis 2001; 32: 794-800.
17. Gebo KA, Moore RD, Keruly JC, Chaisson RE. Risk factors for pneumococcal disease in human immunodeficiency virus-infected patients. J Infect Dis 1996; 173: 857-862.
18. Guerrero M, Kruger S, Saitoh A et al. Pneumonia in HIV-infected patients: a case-control survey of factors involved in risk and prevention. AIDS 1999; 13: 1971-1975.
19. Hung CC, Chen MY, Hsieh SM, Hsiao CF, Sheng WH, Chang SC. Clinical experience of the 23-valent capsular polysaccharide pneumococcal vaccination in HIV-1-infected patients receiving highly active antiretroviral therapy: a prospective observational study. Vaccine 2004; 22: 2006-2012.
20. Kaplan JE, Benson C, Holmes KH, Brooks JT, Pau A, Masur H. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009; 58: 1-207.
21. World Health Organization. Essential prevention and care interventions for adults and adolescents living with HIV in resource-limited settings. Available at (accessed 25 May 2010).
22. French N, Gordon SB, Mwalukomo T et al. A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. N Engl J Med 2010; 362: 812-822.
23. Mond JJ, Lees A, Snapper CM. T cell-independent antigens type 2. Annu Rev Immunol 1995; 13: 655-692.
24. Kroon FP, van Dissel JT, Ravensbergen E, Nibbering PH, van Furth R. Antibodies against pneumococcal polysaccharides after vaccination in HIV-infected individuals: 5-year follow-up of antibody concentrations. Vaccine 1999; 18: 524-530.
25. Rodriguez-Barradas MC, Musher DM, Lahart C et al. Antibody to capsular polysaccharides of Streptococcus pneumoniae after vaccination of human immunodeficiency virus-infected subjects with 23-valent pneumococcal vaccine. J Infect Dis 1992; 165: 553-556.
26. Jay AL. HIV and the Pathogenesis of AIDS, 3rd Ed. Washington: ASM Press, 2007.
27. Chang Q, Abadi J, Alpert P, Pirofski LA. A pneumococcal capsular polysaccharide vaccine induces a repertoire shift with increased V(H)3 expression in peripheral B cells from human immunodeficiency virus (HIV)-uninfected but not HIV-infected persons. J Infect Dis 2000; 181: 1313-1321.
28. Sogaard OS, Schonheyder HC, Bukh AR et al. Pneumococcal conjugate vaccination in persons with HIV: the effect of highly active antiretroviral therapy. AIDS 2010; 24: 1315-1322.
29. Gilks CF, Ojoo SA, Ojoo JC et al. Invasive pneumococcal disease in a cohort of predominantly HIV-1 infected female sex-workers in Nairobi, Kenya. Lancet 1996; 347: 718-723.
30. Teshale EH, Hanson D, Flannery B et al. Effectiveness of 23-valent polysaccharide pneumococcal vaccine on pneumonia in HIV-infected adults in the United States, 1998-2003. Vaccine 2008; 26: 5830-5834.
31. Tumbarello M, Tacconelli E, De Gaetano K et al. Bacterial pneumonia in HIV-infected patients: analysis of risk factors and prognostic indicators. J AIDS 1998; 18: 39-45.
32. Penaranda M, Falco V, Payeras A et al. Effectiveness of polysaccharide pneumococcal vaccine in HIV-infected patients: a case-control study. Clin Infect Dis 2007; 45: e82-e87.
33. Payeras A, Martinez P, Mila J et al. Risk factors in HIV-1-infected patients developing repetitive bacterial infections: toxicological, clinical, specific antibody class responses, opsonophagocytosis and Fc(gamma)RIIa polymorphism characteristics. Clin Exp Immunol 2002; 130: 271-278.
34. Veras MA, Enanoria WT, Castilho EA, Reingold AL. Effectiveness of the polysaccharide pneumococcal vaccine among HIV-infected persons in Brazil: a case control study. BMC Infect Dis 2007; 7: 119.
35. Watera C, Nakiyingi J, Miiro G et al. 23-Valent pneumococcal polysaccharide vaccine in HIV-infected Ugandan adults: 6-year follow-up of a clinical trial cohort. AIDS 2004; 18: 1210-1213.
36. Demaurex N, Gabriel V, Auckenthaler R, Demaurex F, Hirschel B. The efficacy of pneumococcal vaccination in HIV seropositive patients (HIV+): a case-control study. 8th International AIDS Conference. Amsterdam, The Netherlands, July 1992 [Abstract 3890].
37. Lindenburg CE, Langendam MW, Benthem BH, Miedema F, Coutinho RA. No evidence that vaccination with a polysaccharide pneumococcal vaccine protects drug users against all-cause pneumonia. AIDS 2001; 15: 1315-1317.
38. Navin TR, Rimland D, Lennox JL et al. Risk factors for community-acquired pneumonia among persons infected with human immunodeficiency virus. J Infect Dis 2000; 181: 158-164.
39. Lopez-Palomo C, Martin-Zamorano M, Benitez E et al. Pneumonia in HIV-infected patients in the HAART era: incidence, risk, and impact of the pneumococcal vaccination. J Med Virol 2004; 72: 517-524.
40. Rodriguez-Barradas MC, Goulet J, Brown S et al. Impact of pneumococcal vaccination on the incidence of pneumonia by HIV infection status among patients enrolled in the Veterans Aging Cohort 5-Site Study. Clin Infect Dis 2008; 46: 1093-1100.
41. Madeddu G, Porqueddu EM, Cambosu F et al. Bacterial community acquired pneumonia in HIV-infected inpatients in the highly active antiretroviral therapy era. Infection 2008; 36: 231-236.
42. Farrell DJ, Felmingham D, Shackcloth J et al. Non-susceptibility trends and serotype distributions among Streptococcus pneumoniae from community-acquired respiratory tract infections and from bacteraemias in the UK and Ireland, 1999 to 2007. J Antimicrob Chemother 2008; 62: ii87-ii95.
43. Nielsen SV, Henrichsen J. Incidence of invasive pneumococcal disease and distribution of capsular types of pneumococci in Denmark, 1989-94. Epidemiol Infect 1996; 117: 411-416.
44. Nuorti JP, Butler JC, Gelling L, Kool JL, Reingold AL, Vugia DJ. Epidemiologic relation between HIV and invasive pneumococcal disease in San Francisco County, California. Ann Intern Med 2000; 132: 182-190.
45. Thomsen RW. The lesser known effects of statins: benefits on infectious outcomes may be explained by 'healthy user' effect. BMJ 2006; 333: 980-981.
46. Cagigi A, Nilsson A, Pensieroso S, Chiodi F. Dysfunctional B-cell responses during HIV-1 infection: implication for influenza vaccination and highly active antiretroviral therapy. Lancet Infect Dis 2010; 10: 499-503.
47. Qiao X, He B, Chiu A, Knowles DM, Chadburn A, Cerutti A. Human immunodeficiency virus 1 Nef suppresses CD40-dependent immunoglobulin class switching in bystander B cells. Nat Immunol 2006; 7: 302-310.
48. Moir S, Malaspina A, Ho J et al. Normalization of B cell counts and subpopulations after antiretroviral therapy in chronic HIV disease. J Infect Dis 2008; 197: 572-579.
49. Huss A, Scott P, Stuck AE, Trotter C, Egger M. Efficacy of pneumococcal vaccination in adults: a meta-analysis. CMAJ 2009; 180: 48-58.
50. Jefferson T. Pneumococcal vaccines: confronting the confounders. Lancet 2009; 373: 2008-2009.